Amgen isn\u2019t leaning on its laurels even after getting a prompt approval for its carefully manufactured KRAS lung cancer drug, Lumakras, as it has signed a new buyout deal with Teneobio, to further add to its oncology pipeline just after two months of the drug approval.<\/p>\n\n\n\n
The biopharmaceutical company has offered $900 million as upfront money and invested $1.6 billion in biobucks, for the acquisition of Teneobio and its suite of biospecific and multispecific technologies aiming at cancer and other diseases.<\/p>\n\n\n\n
TNB-585, a phase 1 bispecific T cell-engager, targeting metastatic castrate-resistant prostate cancer (mCRPC), is included in the deal along with several preclinical oncology pipeline assets \u201cwith the potential for near-term IND filings,\u201d Amgen said in a SEC filing. <\/p>\n\n\n\n
TNB-585 complements Amgen’s existing prostate cancer portfolio, which includes acapatamab (formerly AMG 160), a half-life extended PSMA-targeted BiTE; and AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy. Both of them are in phase 1. <\/p>\n\n\n\n
Amgen\u2019s M.D. and Executive Vice President R&D, David M. Reese, stated, \u201cThe acquisition of Teneobio will strengthen our ability to develop innovative medicines to treat patients with serious illnesses and to bring to market best-in-class products, particularly with respect to multispecific and bispecific medicines directed against targets in a wide range of diseases across our core therapeutic areas.\u201d<\/p>\n\n\n\n
The deal with Teneobio has come amid Amgen\u2019s another buyout deal with Seattles\u2019 Rodeo Therapeutics for $55 million upfront and another $666 million invested in biobucks, if at all Rodeo\u2019s assets lived up to their hype.<\/p>\n\n\n\n
Prior to that, Amgen has also spent $1.9 billion to buy out Five Prime Therapeutics and its GI cancer drug, bemarituzumab. These deals came after quite a long break taken by Amgen, the last major one being with Onyx, in 2013. <\/p>\n\n\n\n
The current deal in consideration is a bit convoluted due to the fact that Amgen\u2019s rival company, AbbVie, had recently bought out a spin-off from the biotech, TeneoOne, which includes TNB-383B, an anti-CD3\/BCMA bispecific for the treatment of relapsed or refractory multiple myeloma.<\/p>\n\n\n\n
According to Amgen, before the closing of the deal, three affiliates, namely: TeneoTwo (working on an anti-CD19\/CD3), TeneoFour (working on anti-CD38 enzyme inhibitor) and TeneoTen (working on anti-HBV\/CD3) will be given to the Teneobio\u2019s existing stake holders. <\/p>\n\n\n\n
Gilead\u2019s Kite Pharma is also taking part in this, as it has licensed a suite of anitbodies targeting BCMA, from Teneobio, including one which is presently in a phase 1 study for multiple myeloma at the National Cancer Institute.<\/p>\n","protected":false},"excerpt":{"rendered":"
Amgen isn\u2019t leaning on its laurels even after getting a prompt approval for its carefully manufactured KRAS lung cancer drug, Lumakras, as it has signed a new buyout deal with Teneobio, to further add to its oncology pipeline just after two months of the drug approval. The biopharmaceutical company has offered $900 million as upfront […]<\/p>\n","protected":false},"author":1,"featured_media":2021,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[482,52,55,481],"class_list":{"0":"post-2019","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-research-development","8":"tag-amgen","9":"tag-cancer","10":"tag-gilead","11":"tag-teneobio"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=2019"}],"version-history":[{"count":0,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2019\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/2021"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=2019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=2019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=2019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}